An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence

Abstract

This study explored the effect of OPRM1 promoter region DNA methylation on the outcome of treatment with the opioid antagonist naltrexone (NTX) for alcohol dependence (AD). Ninety-three patients with DSM-IV AD [41 African Americans (AAs) and 52 European Americans (EAs)] received double-blind treatment with NTX or placebo for at least three months. Relapse to heavy drinking was assessed during the first 13 weeks of the trial. Peripheral blood methylation levels of 33 CpG units in the OPRM1 promoter region were quantified using Sequenom EpiTYPER technology. Bayesian logistic regression was used to analyze the effects of NTX treatment, CpG methylation, CpG methylation × NTX treatment, and age on AD relapse. The Random Forest machine learning algorithm was applied to select AD relapse predictors. No significant effect of individual OPRM1 promoter CpG units on AD relapse was observed in either AAs or EAs. Age was significantly associated with AD relapse in EAs, among whom older subjects had a lower relapse rate. Random forest analyses revealed that the prediction rate for AD relapse reached 66.0% with five top variables (age and four CpG units; ranked by their importance to AD relapse) in the prediction model. These findings suggest that methylation levels of individual OPRM1 promoter CpG units do not contribute significantly to inter-individual variation in NTX response. However, the age of subjects in combination with a cluster of specific OPRM1 promoter CpG units may affect NTX treatment outcome. Additional studies of OPRM1 DNA methylation changes during and after NTX treatment of AD are needed.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: 44 CpG sites in the OPRM1 promoter region (734 bp).
Fig. 2: Importance of variables to relapse estimated by the Random Forest algorithm.
Fig. 3: Out-of-bag (OOB) error rates versus numbers of most important variables to relapse included in the Random Forest prediction model.

References

  1. 1.

    Niciu MJ, Arias AJ. Targeted opioid receptor antagonists in the treatment of alcohol use disorders. CNS Drugs. 2013;27:777–87.

  2. 2.

    Arias AJ, Sewell RA. Pharmacogenetically driven treatments for alcoholism: are we there yet? CNS Drugs. 2012;26:461–76.

  3. 3.

    Mann K, Roos CR, Hoffmann S, Nakovics H, Lemenager T, Heinz A, et al. Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes. Neuropsychopharmacology. 2018;43:891–9.

  4. 4.

    Anton RF, Latham PK, Voronin KE, Randall PK, Book SW, Hoffman M, et al. Nicotine-use/smoking is associated with the efficacy of naltrexone in the treatment of alcohol dependence. Alcohol Clin Exp Res. 2018;42:751–60.

  5. 5.

    Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546–52.

  6. 6.

    Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. Am J Addict. 2014;23:288–93.

  7. 7.

    McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. Genetic moderators of naltrexone’s effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006;30:1288–96.

  8. 8.

    Ray LA, Bujarski S, Chin PF, Miotto K. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. Neuropsychopharmacology. 2012;37:445–55.

  9. 9.

    Ziauddeen H, Nestor LJ, Subramaniam N, Dodds C, Nathan PJ, Miller SR, et al. Opioid antagonists and the A118G polymorphism in the mu-opioid receptor gene: effects of GSK1521498 and naltrexone in healthy drinkers stratified by OPRM1 genotype. Neuropsychopharmacology. 2016;41:2647–57.

  10. 10.

    Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA cooperative study. Alcohol Clin Exp Res. 2007;31:555–63.

  11. 11.

    Ben Hamida S, Boulos LJ, McNicholas M, Charbogne P, Kieffer BL. Mu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking. Addict Biol. 2019;24:28–39.

  12. 12.

    Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. 2018;19:499–514.

  13. 13.

    Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA. 1998;95:9608–13.

  14. 14.

    Kanherkar RR, Bhatia-Dey N, Csoka AB. Epigenetics across the human lifespan. Front Cell Dev Biol. 2014;2:49.

  15. 15.

    Rassoulzadegan M, Grandjean V, Gounon P, Vincent S, Gillot I, Cuzin F. RNA-mediated non-mendelian inheritance of an epigenetic change in the mouse. Nature. 2006;441:469–74.

  16. 16.

    Zhang H, Gelernter J. Review: DNA methylation and alcohol use disorders: progress and challenges. Am J Addict. 2017;26:502–15.

  17. 17.

    Nielsen DA, Yuferov V, Hamon S, Jackson C, Ho A, Ott J, et al. Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. Neuropsychopharmacology. 2009;34:867–73.

  18. 18.

    Chorbov V, Todorov A, Lynskey M, Cicero T. Elevated levels of DNA methylation at the OPRM1 promoter in blood and sperm from male opioid addicts. J Opioid Manag. 2011;7:258.

  19. 19.

    Zhang H, Herman AI, Kranzler HR, Anton RF, Simen AA, Gelernter J. Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. J Hum Genet. 2012;57:670–5.

  20. 20.

    Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol. 2009;27:361–8.

  21. 21.

    Andria ML, Simon EJ. Localization of promoter elements in the human mu-opioid receptor gene and regulation by DNA methylation. Brain Res Mol Brain Res. 1999;70:54–65.

  22. 22.

    Knothe C, Oertel BG, Ultsch A, Kettner M, Schmidt PH, Wunder C, et al. Pharmacoepigenetics of the role of DNA methylation in mu-opioid receptor expression in different human brain regions. Epigenomics. 2016;8:1583–99.

  23. 23.

    Oertel BG, Doehring A, Roskam B, Kettner M, Hackmann N, Ferreiros N, et al. Genetic-epigenetic interaction modulates mu-opioid receptor regulation. Hum Mol Genet. 2012;21:4751–60.

  24. 24.

    Kaliman P. Epigenetics and meditation. Curr Opin Psychol. 2018;28:76–80.

  25. 25.

    Dejeux E, Ronneberg JA, Solvang H, Bukholm I, Geisler S, Aas T, et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer. 2010;9:68.

  26. 26.

    Herbst A, Vdovin N, Gacesa S, Ofner A, Philipp A, Nagel D, et al. Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer. Int J Cancer. 2017;140:2134–44.

  27. 27.

    Karaglani M, Ragia G, Panagopoulou M, Balgkouranidou I, Nena E, Kolios G, et al. Search for pharmacoepigenetic correlations in type 2 diabetes under sulfonylurea treatment. Exp Clin Endocrinol Diabetes. 2019;127:226–33.

  28. 28.

    Szabo M, Mate B, Csep K, Benedek T. Epigenetic modifications linked to T2D, the heritability gap, and potential therapeutic targets. Biochem Genet. 2018;56:553–74.

  29. 29.

    Swathy B, Banerjee M. Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy. Epigenomics. 2017;9:721–36.

  30. 30.

    Domschke K, Tidow N, Schwarte K, Ziegler C, Lesch KP, Deckert J, et al. Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response. J Neural Transm (Vienna). 2015;122:99–108.

  31. 31.

    Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer’s disease: implications for pharmacogenomics and drug response. Int J Mol Sci. 2015;16:30483–543.

  32. 32.

    Lokk K, Modhukur V, Rajashekar B, Martens K, Magi R, Kolde R, et al. DNA methylome profiling of human tissues identifies global and tissue-specific methylation patterns. Genome Biol. 2014;15:r54.

  33. 33.

    First MB, Spitzer RL, Gibbon M, Williams JBW. User’s guide for structured clinical interview for DSM-IV Axis I disorders - clinician version (SCID-CV). Washington, DC: American Psychiatric Press; 1997.

  34. 34.

    Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study G. Naltrexone in the treatment of alcohol dependence. N. Engl J Med. 2001;345:1734–9.

  35. 35.

    Barker JM, Zhang H, Villafane JJ, Wang TL, Torregrossa MM, Taylor JR. Epigenetic and pharmacological regulation of 5HT3 receptors controls compulsive ethanol seeking in mice. Eur J Neurosci. 2014;39:999–1008.

  36. 36.

    Gelman A, Jakulin A, Pittau MG, Su Y-S. A weakly informative default prior distribution for logistic and other regression models. Ann Appl Stat. 2009;2:1360–83.

  37. 37.

    Breiman L. Random forests. Mach Learn. 2001;45:5–32.

  38. 38.

    Quraishi BM, Zhang H, Everson TM, Ray M, Lockett GA, Holloway JW, et al. Identifying CpG sites associated with eczema via random forest screening of epigenome-scale DNA methylation. Clin Epigenetics. 2015;7:68.

  39. 39.

    Bylander T. stimating generalization error on twoclass datasets using out-of-bag estimates. Mach Learn. 2002;48:287–97.

  40. 40.

    Liaw A, Wiener M. Classification and regression by random forest. R News. 2002;2:18–22.

  41. 41.

    Titus AJ, Gallimore RM, Salas LA, Christensen BC. Cell-type deconvolution from DNA methylation: a review of recent applications. Hum Mol Genet. 2017;26(R2):R216–24.

  42. 42.

    Koestler DC, Christensen B, Karagas MR, Marsit CJ, Langevin SM, Kelsey KT, et al. Blood-based profiles of DNA methylation predict the underlying distribution of cell types: a validation analysis. Epigenetics. 2013;8:816–26.

  43. 43.

    Jacobsen KX, Hoistad M, Staines WA, Fuxe K. The distribution of dopamine D1 receptor and mu-opioid receptor 1 receptor immunoreactivities in the amygdala and interstitial nucleus of the posterior limb of the anterior commissure: relationships to tyrosine hydroxylase and opioid peptide terminal systems. Neuroscience. 2006;141:2007–18.

  44. 44.

    Satre DD, Chi FW, Mertens JR, Weisner CM. Effects of age and life transitions on alcohol and drug treatment outcome over nine years. J Stud Alcohol Drugs. 2012;73:459–68.

  45. 45.

    Hernandez DG, Nalls MA, Gibbs JR, Arepalli S, van der Brug M, Chong S, et al. Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet. 2011;20:1164–72.

Download references

Acknowledgements

We thank all participants in this study. We are grateful to Dr Joel Gelernter and his colleagues at Yale University School of Medicine for providing DNA samples and clinical data for the conduct of this study.

Author information

Correspondence to Huiping Zhang.

Ethics declarations

Conflict of interest

This work was supported by grants (R21AA023068 and R01AA025080) from the National Institute on Alcohol Abuse and Alcoholism. HRK is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative (ACTIVE), which during the past three years was supported by AbbVie, Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, and Pfizer. HRK is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. All other authors declare that they have no conflict of interest. The authors alone are responsible for the content and writing of this paper.

Ethical approval

Ethics statements: The study was exempted from a specific ethical approval by Boston University School of Medicine in accordance with local/national guidelines. This study only involved DNA methylation data analysis, and the de-identified DNA samples were from our collaborator Dr Joel Gelernter at Yale University School of Medicine. Patient samples and demographic information were collected as part of previous studies (Krystal et al. [34]; Gelernter et al. [10]).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lin, Y., Kranzler, H.R., Farrer, L.A. et al. An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence. Pharmacogenomics J (2020). https://doi.org/10.1038/s41397-020-0158-1

Download citation